Medical products company Acuron is planning to relist on the Australian Stock Exchange as WA Business News goes to press.
The company received strong shareholder support at a general meeting on July 7 to change its name from Auridiam to Acuron and to change its activities from diamond exploration to sale of Vacutex wound care.
Vacutex is a treatment for wounds such as ulcers. It has a wicking effect that draws moisture away from such wounds, improving recovery times.
Acuron managing director George Cameron-Dow said sales of Vacutex were underway in the UK where the product was National Health Service-registered, in Australia where it has Therapeutic Goods Administration approval and in the Middle East.
"The advanced wound care market is worth more than $55 million in Australia and more than $US1.4 billion worldwide and the sector is forecast to grow at an annual rate of between 7 per cent and 11 per cent.